Allarity Therapeutics, Inc. ALLR PHARMA
Company Overview
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +25.00% |
| 6 Months: | +0.81% |
| 3 Months: | -20.89% |
| 1 Month: | -10.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)38.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 36.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALLR Allarity Therapeutics, Inc. PHARMA | 1.25 | -1.58 | $19.89M | 0.00% | -128.26% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 25.00K |
| Gross Profit | - | - | - | - | - | - | -1.25M | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.97M | -2.46M | -4.38M | -3.97M | -18.31M | -4.84M | -4.56M | -3.67M | -4.16M | -4.43M | -4.24M | -3.37M | -12.31M | -3.04M | -4.13M | -2.52M | -2.69M |
| Net Income | - | -3.08M | -5.40M | -1.35M | -3.08M | -5.10M | -5.04M | -3.35M | -2.38M | -4.45M | -3.84M | -1.63M | -11.59M | -2.73M | -2.32M | -2.81M | -2.75M |
| Diluted EPS | - | - | -1.08 | -0.17 | -19.64 | -53.90 | -934.29 | -6,356.06 | -525.53 | -2.03 | -22.14 | -0.11 | - | - | - | - | - |
| R&D Expense | 1.01M | 1.25M | 2.28M | 1.35M | 1.29M | 1.70M | 3.00M | 1.43M | 1.10M | 1.95M | 2.17M | 1.06M | 1.02M | 1.40M | 2.32M | 1.20M | 1.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 320.00K |
| Gross Profit | - | - | -2.27M | - | - | - |
| Operating Income | -8.32M | -26.56M | -34.46M | -17.13M | -27.24M | -12.61M |
| Net Income | -6.62M | -26.65M | -16.06M | -11.90M | -24.52M | -11.23M |
| Diluted EPS | - | -4.19 | -3,093.42 | -10.26 | - | - |
| R&D Expense | 4.22M | 14.20M | 6.93M | 7.10M | 6.10M | 6.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 33.40M | 49.63M | 14.54M | 11.86M | 22.65M | 18.26M |
| Total Equity | 20.04M | 24.44M | 18.15M | -113.00K | -2.75M | 11.81M | 9.83M |
| Cash & Equivalents | - | - | - | 2.03M | 166.00K | 19.53M | 14.69M |
| Long Term Debt | - | - | - | 2.64M | 2.69M | - | - |
| Total Liabilities | - | 8.96M | 30.85M | 12.65M | 14.61M | 10.84M | 8.43M |
| Current Liabilities | - | 5.53M | 20.72M | 11.22M | 14.17M | 10.84M | 8.43M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.25M | -14.89M | -16.82M | -12.74M | -17.35M | -14.82M |
| Investing Cash Flow | -3.00K | 1.00M | 791.00K | 0 | -298.00K | -8.00K |
| Financing Cash Flow | 6.03M | 33.82M | -1.31M | 10.99M | 36.79M | 10.65M |
| Capital Expenditure | -3.00K | - | -18.00K | -0 | -298.00K | -8.00K |
| Free Cash Flow | -7.25M | - | -16.84M | -12.74M | -17.65M | -14.83M |
| Share Buybacks | - | - | - | - | 0 | 3.19M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -3,939.1% |
| Net Margin % | - | - | - | - | - | -3,509.7% |
| ROE % | -27.1% | -146.8% | 14,210.6% | 432.6% | -207.6% | -114.3% |
| ROCE % | -29.8% | -91.8% | -1,037.4% | 743.1% | -230.6% | -128.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Renaissance Technologies, LLC | 2.08% | 331.51K | $401.12K |
| 2 | Vanguard Capital Management LLC | 1.08% | 171.79K | $207.87K |
| 3 | Geode Capital Management, LLC | 0.97% | 154.87K | $187.39K |
| 4 | State Street Corporation | 0.86% | 137.60K | $166.50K |
| 5 | Militia Capital Management LLC | 0.62% | 98.98K | $119.76K |
| 6 | Citadel Advisors Llc | 0.58% | 91.75K | $111.02K |
| 7 | Vanguard Fiduciary Trust Co | 0.47% | 74.91K | $90.64K |
| 8 | Northern Trust Corporation | 0.23% | 36.53K | $44.21K |
| 9 | HRT Financial LP | 0.23% | 37.00K | $44.77K |
| 10 | Jane Street Group, LLC | 0.23% | 36.02K | $43.59K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALLR
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042 - AACR 2026 data linked higher…
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-…
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 c…
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.
ALLR — Frequently Asked Questions
What is the current share price of Allarity Therapeutics, Inc. (ALLR)?
As of 2026-09-19 21:16 PDT, Allarity Therapeutics, Inc. (ALLR) trades at $1.25 on NasdaqCM. Its 52-week range is $0.81 to $1.97.
What is the market capitalisation of ALLR?
Allarity Therapeutics, Inc. (ALLR) has a market capitalisation of $19.89M on NasdaqCM.
What is the P/E ratio of ALLR?
ALLR trades at a trailing price-to-earnings (P/E) ratio of -1.58. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.68.
Is ALLR a good stock to buy?
This page provides a data-driven analysis of Allarity Therapeutics, Inc. (ALLR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.